These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. The effect of lomitapide on cardiovascular outcome measures in homozygous familial hypercholesterolemia: A modelling analysis. Leipold R; Raal F; Ishak J; Hovingh K; Phillips H Eur J Prev Cardiol; 2017 Nov; 24(17):1843-1850. PubMed ID: 28925748 [TBL] [Abstract][Full Text] [Related]
3. Lomitapide-a Microsomal Triglyceride Transfer Protein Inhibitor for Homozygous Familial Hypercholesterolemia. Stefanutti C Curr Atheroscler Rep; 2020 Jun; 22(8):38. PubMed ID: 32557261 [TBL] [Abstract][Full Text] [Related]
4. Long-term safety and efficacy of lomitapide in patients with homozygous familial hypercholesterolemia: Five-year data from the Lomitapide Observational Worldwide Evaluation Registry (LOWER). Underberg JA; Cannon CP; Larrey D; Makris L; Blom D; Phillips H J Clin Lipidol; 2020; 14(6):807-817. PubMed ID: 33023859 [TBL] [Abstract][Full Text] [Related]
5. Lomitapide: A novel agent for the treatment of homozygous familial hypercholesterolemia. Davis KA; Miyares MA Am J Health Syst Pharm; 2014 Jun; 71(12):1001-8. PubMed ID: 24865757 [TBL] [Abstract][Full Text] [Related]
6. Case report: The efficacy and safety of lomitapide in a homozygous familial hypercholesterolemic child. Chacra APM; Ferrari MC; Rocha VZ; Santos RD J Clin Lipidol; 2019; 13(3):397-401. PubMed ID: 30948303 [TBL] [Abstract][Full Text] [Related]
7. Treating homozygous familial hypercholesterolemia in a real-world setting: Experiences with lomitapide. Roeters van Lennep J; Averna M; Alonso R J Clin Lipidol; 2015; 9(4):607-17. PubMed ID: 26228681 [TBL] [Abstract][Full Text] [Related]
8. Lomitapide: a review of its use in adults with homozygous familial hypercholesterolemia. Perry CM Am J Cardiovasc Drugs; 2013 Aug; 13(4):285-96. PubMed ID: 23720215 [TBL] [Abstract][Full Text] [Related]
9. Management of homozygous familial hypercholesterolemia in real-world clinical practice: A report of 7 Italian patients treated in Rome with lomitapide and lipoprotein apheresis. Stefanutti C; Morozzi C; Di Giacomo S; Sovrano B; Mesce D; Grossi A J Clin Lipidol; 2016; 10(4):782-789. PubMed ID: 27578108 [TBL] [Abstract][Full Text] [Related]
10. Lomitapide in homozygous familial hypercholesterolemia: cardiology perspective from a single-center experience. Sperlongano S; Gragnano F; Natale F; D'Erasmo L; Concilio C; Cesaro A; Golia E; Crisci M; Sperlongano R; Fimiani F; Russo M; Arca M; Limongelli G; Calabrò P J Cardiovasc Med (Hagerstown); 2018 Mar; 19(3):83-90. PubMed ID: 29389816 [TBL] [Abstract][Full Text] [Related]
11. The lipid-lowering effects of lomitapide are unaffected by adjunctive apheresis in patients with homozygous familial hypercholesterolaemia - a post-hoc analysis of a Phase 3, single-arm, open-label trial. Stefanutti C; Blom DJ; Averna MR; Meagher EA; Theron Hd; Marais AD; Hegele RA; Sirtori CR; Shah PK; Gaudet D; Vigna GB; Sachais BS; Di Giacomo S; du Plessis AM; Bloedon LT; Balser J; Rader DJ; Cuchel M; Atherosclerosis; 2015 Jun; 240(2):408-14. PubMed ID: 25897792 [TBL] [Abstract][Full Text] [Related]
12. Lomitapide for the management of homozygous familial hypercholesterolemia. deGoma EM Rev Cardiovasc Med; 2014; 15(2):109-18. PubMed ID: 25051128 [TBL] [Abstract][Full Text] [Related]
13. Microsomal triglyceride transfer protein inhibitor (lomitapide) efficacy in the treatment of patients with homozygous familial hypercholesterolaemia. Kolovou G; Diakoumakou O; Kolovou V; Fountas E; Stratakis S; Zacharis E; Liberopoulos EN; Matsouka F; Tsoutsinos A; Mastorakou I; Katsikas T; Mavrogeni S; Hatzigeorgiou G Eur J Prev Cardiol; 2020 Jan; 27(2):157-165. PubMed ID: 31403880 [TBL] [Abstract][Full Text] [Related]
14. Review of the long-term safety of lomitapide: a microsomal triglycerides transfer protein inhibitor for treating homozygous familial hypercholesterolemia. Khoury E; Brisson D; Roy N; Tremblay G; Gaudet D Expert Opin Drug Saf; 2019 May; 18(5):403-414. PubMed ID: 30945578 [TBL] [Abstract][Full Text] [Related]
15. Efficacy and Safety of Lomitapide in Hypercholesterolemia. Liu X; Men P; Wang Y; Zhai S; Zhao Z; Liu G Am J Cardiovasc Drugs; 2017 Aug; 17(4):299-309. PubMed ID: 28255870 [TBL] [Abstract][Full Text] [Related]
16. Efficacy of Lomitapide in the Treatment of Familial Homozygous Hypercholesterolemia: Results of a Real-World Clinical Experience in Italy. D'Erasmo L; Cefalù AB; Noto D; Giammanco A; Averna M; Pintus P; Medde P; Vigna GB; Sirtori C; Calabresi L; Pavanello C; Bucci M; Sabbà C; Suppressa P; Natale F; Calabrò P; Sampietro T; Bigazzi F; Sbrana F; Bonomo K; Sileo F; Arca M Adv Ther; 2017 May; 34(5):1200-1210. PubMed ID: 28432645 [TBL] [Abstract][Full Text] [Related]
17. Safety and Efficacy of Lomitapide in Japanese Patients with Homozygous Familial Hypercholesterolemia (HoFH): Results from the AEGR-733-301 Long-Term Extension Study. Nohara A; Otsubo Y; Yanagi K; Yoshida M; Ikewaki K; Harada-Shiba M; Jurecka A J Atheroscler Thromb; 2019 Apr; 26(4):368-377. PubMed ID: 30259883 [TBL] [Abstract][Full Text] [Related]
18. Individual analysis of patients with HoFH participating in a phase 3 trial with lomitapide: The Italian cohort. Averna M; Cefalù AB; Stefanutti C; Di Giacomo S; Sirtori CR; Vigna G Nutr Metab Cardiovasc Dis; 2016 Jan; 26(1):36-44. PubMed ID: 26723464 [TBL] [Abstract][Full Text] [Related]
19. Clinical experience of lomitapide therapy in patients with homozygous familial hypercholesterolaemia. Cuchel M; Blom DJ; Averna MR Atheroscler Suppl; 2014 Sep; 15(2):33-45. PubMed ID: 25257075 [TBL] [Abstract][Full Text] [Related]
20. Lomitapide for use in patients with homozygous familial hypercholesterolemia: a narrative review. Neef D; Berthold HK; Gouni-Berthold I Expert Rev Clin Pharmacol; 2016; 9(5):655-63. PubMed ID: 26943823 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]